 Novan, Inc. the Company or Novan NOVN today announced that the Company has received meeting minutes from the April 1, 2020 Type C meeting with the U.S. Food and Drug Administration FDA regarding SB206 for the treatment of molluscum contagiosum molluscum. Based on guidance the Company received during the meeting and subsequently contained within the meeting minutes, Novan is preparing to conduct one additional pivotal trial B-SIMPLE4, which, if successful, could be supported by the previously completed B-SIMPLE2 trial in a future New Drug Application NDA. 